DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05812183

WithdrawnPhase 4

Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

The Effect of Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Patients with Obesity: a Feasibility Study

Assets

Liraglutide / Semaglutide / Tirzepatide

Listed sites

0

Recruiting sites

—

Enrollment

—

actual

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Dyspnea

Identifiers

Registered as

NCT IDNCT05812183
Org study ID22-001915

Timeline

Milestones

Study first posted2023-04-13actual
Study start2023-07-09actual
Primary completion2025-02-12estimated
Study completion2025-02-12actual
Last update posted2025-02-14actual

Assets

Investigational agents

LiraglutideSemaglutideTirzepatide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

1. Male or female ≥18 years of age.

2. All patients undergoing gastric sleeve resection for serious obesity at the Ronald Reagan medical center will be considered for enrollment in the experimental group.

3. English/Spanish speakers.

4. The patients included will be with preserved cognition and a capacity to understand questionnaires.

5. Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion criteria

1. Serious cardiovascular disease, previous gastrointestinal surgery, psychological concerns (mental disorders and dementia), recently hospitalized, pulmonary diseases, renal failure, or history of malignancy.

2. Undergoing procedures other than gastric sleeve resection or are having these operations after they have had other bariatric procedures.

3. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Patient-reported / QoL

2 endpoints
Primary/protocol endpoint

Dyspnea

Time frame:12 months

descriptive, improvement

Secondary/protocol endpoint

Health related quality of life

Time frame:12 months

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.